IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
Rhea-AI Summary
IM Cannabis (NASDAQ: IMCC) closed a US$225,000 convertible note financing with an institutional investor. The note carries an 8% annual interest rate, a 10% original issue discount, and is repayable only in common shares.
The conversion price is the lower of US$0.152 per share or 90% of the lowest 20-day VWAP, with a US$0.0303 floor and a 4.99% ownership cap. IM Cannabis also issued warrants for up to 1,483,386 shares at C$0.22, exercisable immediately until July 1, 2031. Net proceeds are earmarked for general corporate purposes, with plans to file a resale registration statement and securities subject to a four month and one day hold period.
Positive
- US$225,000 raised via convertible note for general corporate purposes
- Convertible note carries 8% annual interest rate before any default
- Warrants exercisable for up to 1,483,386 shares at C$0.22
- Ownership cap of 4.99% limits single-investor concentration risk
Negative
- Mandatory share settlement creates potential dilution for existing shareholders
- Original issue discount of 10% increases effective financing cost
- Interest rate can rise to 14% upon an event of default
- Variable conversion price tied to 90% of lowest 20-day VWAP may pressure equity
News Market Reaction – IMCC
In the Jul 2 session, IMCC declined 1.35%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 18 | asset sale intent | Positive | -17.4% | Planned sale of European activities to reduce debt by about C$10.5M. |
| Jun 09 | resale registration | Negative | -8.7% | Form F-3 resale registration for prior convertible notes and warrants. |
| Jun 03 | note financing | Negative | +1.8% | US$225,000 convertible note with share-only repayment and attached warrants. |
| May 13 | earnings report | Negative | -3.3% | Q1 2026 results showing revenue decline and net loss of $2.5M. |
| May 07 | note financings | Negative | -6.7% | Two convertible note deals totaling US$550,000 with immediate warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financings and balance-sheet actions have often led to negative price reactions, with occasional divergences on similar convertible note deals.
Key Terms
convertible note financial
original issuance discount financial
volume-weighted average price financial
beneficial ownership cap financial
form f-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pursuant to a note purchase agreement between the Company and Lender dated July 1, 2026 (the "July Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of
The July Note bears interest at a rate of
The conversion price in the July Note is set to the lower of (i) a fixed price of
In connection with the July Note, the Company issued a warrant to purchase up to 1,483,386 Common Shares (the "July Note Warrants") at an exercise price of
The Company intends to use the net proceeds from the July Note for general corporate purposes.
In connection with the July Note Purchase Agreement, the Company has agreed to reserve sufficient Common Shares for issuance upon conversion of the July Note and exercise of the July Note Warrants and to file a resale registration statement on Form F-3 with the
All securities issued under the financing described above are subject to: (i) a four month and one day hold period from the date of issuance and (ii) applicable legends as required pursuant to the
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.
The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Company Contact:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the receipt of and use of proceeds from the financing and the preparation, timing and filing of the registration statement with the SEC. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war Israel is facing on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company's inability to take advantage of the legalization of medicinal cannabis in Germany; the Company's inability to use the proceeds as set out herein; and the Company's inability to file a registration statement in the timelines outlined herein or at all.
Please see the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/im-cannabis-raises-us225-000-of-gross-proceeds-in-convertible-note-financing-302816114.html
SOURCE IM Cannabis Corp.